Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) was $7.63 for the day, up 1.73% from the previous closing price of $7.5. In other words, the price has increased by $1.73 from its previous closing price. On the day, 0.58 million shares were traded. GLUE stock price reached its highest trading level at $7.7882 during the session, while it also had its lowest trading level at $7.46.
Ratios:
Our analysis of GLUE’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.76. For the most recent quarter (mrq), Quick Ratio is recorded 7.16 and its Current Ratio is at 7.16. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $11 from $14 previously.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $11.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 03 ’25 when Dunn Edmund sold 2,062 shares for $4.45 per share. The transaction valued at 9,174 led to the insider holds 23,732 shares of the business.
Leo Chandra P. bought 10,000 shares of GLUE for $58,383 on Mar 24 ’25. The Director now owns 10,000 shares after completing the transaction at $5.84 per share. On Oct 28 ’24, another insider, Versant Venture Capital VI, L., who serves as the 10% Owner of the company, sold 89,990 shares for $9.66 each. As a result, the insider received 869,240 and left with 2,007,948 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 471223872 and an Enterprise Value of 221760848. As of this moment, Monte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.65 while its Price-to-Book (P/B) ratio in mrq is 1.76. Its current Enterprise Value per Revenue stands at 1.246 whereas that against EBITDA is 9.519.
Stock Price History:
The Beta on a monthly basis for GLUE is 1.54, which has changed by 0.49901772 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, GLUE has reached a high of $12.40, while it has fallen to a 52-week low of $3.50. The 50-Day Moving Average of the stock is 41.95%, while the 200-Day Moving Average is calculated to be 40.73%.
Shares Statistics:
GLUE traded an average of 1.06M shares per day over the past three months and 929580 shares per day over the past ten days. A total of 61.72M shares are outstanding, with a floating share count of 46.42M. Insiders hold about 24.83% of the company’s shares, while institutions hold 79.19% stake in the company. Shares short for GLUE as of 1757894400 were 8239631 with a Short Ratio of 7.76, compared to 1755216000 on 8321153. Therefore, it implies a Short% of Shares Outstanding of 8239631 and a Short% of Float of 17.669999999999998.
Earnings Estimates
The market rating of Monte Rosa Therapeutics Inc (GLUE) is currently shaped by the ongoing analysis conducted by 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.09, with high estimates of $1.01 and low estimates of -$0.49.
Analysts are recommending an EPS of between $1.29 and -$0.54 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is -$1.29, with 8.0 analysts recommending between $0.12 and -$2.1.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for GLUE’s current fiscal year. The highest revenue estimate was $248.1M, while the lowest revenue estimate was $108M, resulting in an average revenue estimate of $146.28M. In the same quarter a year ago, actual revenue was $75.62M
